Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Patients Who

Daiichi Sankyo logo

Daiichi, ArQule cancer drug tivantinib flunks another trial

Fails to meet endpoint in colorectal cancer study

Daiichi Sankyo launches Alzheimer’s campaign

Disease awareness drive will include TV commercials, newspaper adverts and a website

- PMLiVE

Pharma’s 2012 in … gamification

Boehringer’s headline-grabbing Syrum wasn’t this year's only use of gaming techniques

- PMLiVE

MP: Daiichi Sankyo’s expansion is endorsement of UK life sciences

Pharma company enlarges its UK early-stage development base

- PMLiVE

Merz, Lilly and Daiichi-Sankyo breach ABPI code

Pharma companies 'named and shamed' for inappropriate marketing in the UK

- PMLiVE

Eliquis cleared in EU for stroke prevention in AF

Follows last year’s approval for the prevention of VTE after surgery for BMS and Pfizer's drug

- PMLiVE

Guide to gamification

How to execute digital: Using gaming as part of a pharma marketing campaign

- PMLiVE

Data-driven pharma marketing

The most successful organisations of the future will be the ones that are able to ride the ‘data tsunami’ to gain a competitive advantage – and understanding data generated by...

New data backs Pfizer’s Eliquis in atrial fibrillation

Findings bode well for the drug's commercial prospects

Daiichi and ArQule pull late-stage study of lung cancer drug

Fails to reach primary endpoint of overall survival

- PMLiVE

Treating the brain with software

Clinical trials of game-like software designed to re-programme the brain and tackle some of the most intractable symptoms of schizophrenia could usher in a new way to treat a range...

FDA sets new date for Eliquis review in atrial fibrillation

US regulator had asked for more data from Pfizer and BMS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links